Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain.

• European Society of Gene and Cell Therapy (ESGCT) Congress
  Title: A transformative LDL-cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates
  Session Date and Time: Thursday, October 9, 5:00 p.m. CEST / 11:00 a.m. ET  
  Session Title: 9A: Gene Editing II, Ex Vivo Applications
  Room: Parallel A
  Presenter: Linda Burkly, Ph.D, Executive Vice President and Chief Scientific Officer, Editas Medicine 
  Final Abstract Number: OR069

Abstracts are available to registrants on the ESGCT website. The oral presentation will also be posted to the “Posters & Presentations” section of the Company’s website at the time of the presentation and will remain accessible following the event.

In addition, management will participate in the following upcoming investor conferences in October:

• H.C. Wainwright Genetic Medicines Virtual Conference
  Format: Fireside Chat
  Date: Tuesday, October 14, 7:00 a.m. ET
  Location: Virtual

• Chardan 9^th Annual Genetic Medicines Conference 
  Panel Discussion: Genome Editing: Next Wave Technologies
  Date: Tuesday, October 21, 8:45 a.m. ET
  Location: New York, NY

To access a live webcast of the presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.

About Editas Medicine 
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. 

Investor and Media Contacts: 
ir@editasmed.com 
media@editasmed.com  

Source: Editas Medicine, Inc.